No Data
Shandong Jincheng Pharmaceutical Group (300233.SZ): The company's application for the safety assessment of the transgenic astaxanthin product is currently underway.
On March 4, Gelonghui reported that Shandong Jincheng Pharmaceutical Group (300233.SZ) stated on the investor interaction platform that the safety evaluation of the transgenic astaxanthin product it applied for is currently underway.
Shandong Jincheng Pharmaceutical Group (300233.SZ): Jincheng Pharmaceuticals and Jincheng Taier have been re-certified as high-tech enterprises.
On February 28, Gelonghui reported that Shandong Jincheng Pharmaceutical Group (300233.SZ) announced that its two subsidiaries, ShanDong Jincheng Pharmaceutical Chemical Co., Ltd. (referred to as "Jincheng Jihua") and Peking Jincheng Taier Pharmaceutical Co., Ltd. (referred to as "Jincheng Taier"), have again passed the certification as high-tech enterprises and received the "High-Tech Enterprise Certificate" respectively.
Shandong Jincheng Pharmaceutical Group (300233.SZ): not involved in investments in the Siasun Robot&Automation field.
Gelonghui, February 27丨 Shandong Jincheng Pharmaceutical Group (300233.SZ) stated on the investor interaction platform that the company is currently not involved in investments in the robot field.
Shandong Jincheng Pharmaceutical Group (300233.SZ): Its subsidiary Jincheng Biological, as a raw material supplier for pet formulations, does not rule out the possibility of developing Business in pet formulations through collaboration in the future.
On February 20, Gelonghui reported that Shandong Jincheng Pharmaceutical Group (300233.SZ) stated on the investor interaction platform that its subsidiary Jincheng Biotech, as a raw material supplier for pet formulations, provides raw materials to domestic and overseas downstream customers, and in the future does not rule out expanding the business in pet formulations through collaboration.
Shandong Jincheng Pharmaceutical Group (300233.SZ): In the first three quarters of 2024, a dividend distribution of 10 shares for every 1.5 yuan; the record date for the distribution of shares is February 14.
On February 10, Gelonghui reported that Shandong Jincheng Pharmaceutical Group (300233.SZ) announced that the implementation plan for equity distribution in the first three quarters of 2024 is as follows: based on the existing total share capital of the company, excluding the repurchased shares of 4,543,000.00 shares, totaling 379,331,587.00 shares, a cash distribution of 1.500000 yuan (including tax) will be made for every 10 shares to all shareholders. The equity registration date for this distribution is February 14, 2025. The ex-dividend date for this equity distribution is February 17, 2025.
Shandong Jincheng Pharmaceutical Group (300233.SZ) proposes to distribute 1.5 yuan for every 10 shares on February 17, with the rights and interests being adjusted.
Shandong Jincheng Pharmaceutical Group (300233.SZ) announced that the proposed dividend distribution for the first three quarters of 2024 is: a distribution of... for every 10 shares.
Shandong Jincheng Pharmaceutical Group Co., Ltd's (SZSE:300233) 29% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio